GlassScriptPhysician profile
Jeffrey Mank
NPI 1568200814
$10,603.52
in general payments reported to CMS, 2019-2025
21 companies · $8,921 in 2025
The $8,921 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,683 · 2025: $8,921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,949 · Consulting Fee: $4,200 · Education: $317 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,948.98 |
| Consulting Fee | $4,200.00 |
| Education | $316.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $137.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,475.32 | 2024-2025 | |
| Abbvie INC. | $1,124.30 | 2024-2025 | |
| Galderma Laboratories, L.P. | $753.54 | 2024-2025 | Nemluvio, Aklief |
| Lilly USA, LLC | $548.84 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Leo Pharma INC. | $539.61 | 2024-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $486.01 | 2024-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $443.22 | 2024-2025 | Dupixent |
| Ucb, INC. | $366.47 | 2024-2025 | Bimzelx |
| Janssen Biotech, INC. | $329.13 | 2025 | Tremfya, Simponi Aria, Stelara |
| Incyte Corporation | $281.60 | 2024-2025 | Opzelura, Opzelura |
| Organon LLC | $276.70 | 2025 | Vtama, Nexplanon |
| Amgen INC. | $276.17 | 2024-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $211.68 | 2024-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $117.79 | 2025 | |
| Genzyme Corporation | $116.95 | 2024-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $92.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $46.98 | 2024-2025 | |
| Journey Medical Corporation | $39.32 | 2025 | |
| Ani Pharmaceuticals, INC. | $31.30 | 2025 | Purified Cortrophin Gel |
| Dermavant Sciences, INC. | $27.89 | 2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.70 | 2025 | Arazlo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Mank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.